-
Morning Market Losers
Monday, June 27, 2011 - 9:53am | 111Pain Therapeutics (NASDAQ: PTIE) dipped 26.60% to $3.89 at 9:50 am. Pfizer (NYSE: PFE) and PTIE received a Complete Response Letter from the US Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY. Malvern Federal Bancorp Inc (NASDAQ: MLVF) fell 12....
-
Morning Market Movers
Monday, June 27, 2011 - 9:46am | 151Icagen Inc (NASDAQ: ICGN) shares surged 129.18% to $5.50 at 9:45 am. Pfizer Inc (NYSE: PFE) reported that it is considering a strategic transaction with Icagen. Tiens Biotech Group (USA) Inc (AMEX: TBV) shares gained 64.08% to $1.69. TBV shares have dropped 43.72% over the past 52 weeks, while the...
-
Generex Provides Clarification of Facts
Monday, June 27, 2011 - 9:05am | 427Generex Biotechnology Corporation (OTC: GNBT) today provided a clarification of facts arising out of a blog post on Friday, June 24, 2011. Following that blog post, the price of the Company's common stock fell more than 20% and more than 4 million shares were traded. The author of the blog post...
-
Piper Jaffray Reiterates Neutral Rating, $44 PT on Endo Pharmaceuticals
Monday, June 27, 2011 - 8:54am | 136Piper Jaffray is reiterating its Neutral rating and $44 PT on Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP). “On Friday, Endo announced the recall of two lots of legacy product Endocet (a combination of oxycodone and acetaminophen), as well as four lots of two generic products made by...
-
Benzingas Top Pre-Market NASDAQ Losers
Monday, June 27, 2011 - 8:24am | 148Pain Therapeutics (NASDAQ: PTIE) dipped 23.96% to $4.03 in the pre-market session. Pfizer (NYSE: PFE) and PTIE received a Complete Response Letter from the US Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY. Fundtech Ltd (NASDAQ: FNDT) dropped 0...
-
Piper Jaffray Maintains OW Rating and $4 PT on Durect
Monday, June 27, 2011 - 8:16am | 158On Friday, Durect (NASDAQ: DRRX) announced that partner Pfizer (NYSE: PFE) received a Complete Response letter from the FDA regarding tamper-resistant formulation of extended-release oxycodone Remoxy, Piper Jaffray reports. “Though Pfizer did not discuss the details of the letter, recall that...
-
Benzingas Top Pre-Market NASDAQ Gainers
Monday, June 27, 2011 - 8:13am | 128Icagen Inc (NASDAQ: ICGN) shares advanced 129.59% to $5.51 in the pre-market session. Pfizer(NYSE: PFE) reported that it is considering a strategic transaction with Icagen. Sangamo BioSciences Inc (NASDAQ: SGMO) shares advanced 3.82% to $6.25 in the pre-market session. SGMO had no debt for the...
-
Goldman Sachs Reiterates Neutral on Bristol Myers Squibb and AstraZeneca
Monday, June 27, 2011 - 8:12am | 75Goldman Sachs reiterated its Neutral rating on Bristol Myers Squibb (NYSE: BMY) and AstraZeneca (NYSE: AZN). On Friday, AstraZeneca added 0.22% to its value to close the week at $49. Its shares lost all of Friday's gains in today's pre-market trading, however, falling 1.24% to $48.29. At the same...
-
Icagen Rises on M&A Speculation with Pfizer -AP
Monday, June 27, 2011 - 8:06am | 77The Associated Press reports that Icagen (NASDAQ: ICGN) is rising on merger speculation with Pfizer (NYSE: PFE). The Reuters story on the AP article can be found via the link above. At last check, shares of Icagen were trading over 133% higher in pre-market trading versus Friday's closing price.
-
Morgan Stanley Provides Color on Bristol Myers Squibb
Monday, June 27, 2011 - 8:03am | 134Morgan Stanley provided color on Bristol Myers Squibb (NYSE: BMY). In a research report published today, Morgan Stanley commented on the performance of the company's drug dapagliflozin. In the report, Morgan Stanley states, “Dapagliflozin (SGLT2 for diabetes) showed numerically higher bladder...
-
Citi Maintains Hold Rating on Eli Lilly
Monday, June 27, 2011 - 7:34am | 206Citi is maintaining its Hold rating on shares of Eli Lilly (NYSE: LLY). “LLY announced results for its fully humanized GLP-1 Fc (LY2189265) thorough QT (tQT) analysis at the American Diabetes Association meeting in San Diego. In a single-dose study of supratherapeutic GLP-1Fc doses in health...
-
A Peek Into The Market Before The Trading Starts
Monday, June 27, 2011 - 7:32am | 442Pre-open movers US stock futures are higher this morning, as investors are awaiting data on consumer spending. Futures on the Dow Jones Industrial Average surged 26 points to 11,907.00 and futures on the S&P 500 stock index rose 4.20 points to 1,267.20. Nasdaq 100 futures jumped 7.75 points to...
-
Citi Maintains Buy on Mylan
Monday, June 27, 2011 - 7:30am | 128Citi is out with its report today on Mylan (NYSE: MYL), maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Mylan Buy/High Risk (1H) with a $29 target. Mylan currently trades at the low end of its historical average forward P/E multiple, however, the company is generating...
-
Jefferies Maintains Buy on Amylin Pharmaceuticals
Monday, June 27, 2011 - 7:25am | 97Jefferies is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Buy. In a note to clients, Jefferies writes, "We viewed AMLN's presentations on QT data from DURATION-1 and new data on Byetta once monthly as incremental positives for the stock. We also see the...
-
Columbia Laboratories NDA for PROCHIEVE Gel Accepted for Filing by FDA
Monday, June 27, 2011 - 6:58am | 179Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with...